Initial uptake reflects strong efficacy-driven positioning relative to established therapies, though familiarity gaps, payer controls, and measured promotional visibility shape
New Patient Voice Dynamix™ research highlights that even with patients’ high awareness of options and active engagement in their care,
The FDA has rejected AstraZeneca’s subcutaneous version of lupus treatment Saphnelo, but the company is moving quickly to address the
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain hesitant on whether its efficacy outweighs the possible risks,
Nearly half of US rheumatologists expect Gazyva to meaningfully reshape SLE treatment pathways, while CAR T-cell therapy is viewed as applicable to
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift. EXTON,
Patient-reported data reveal substantial gaps between clinical perception and lived experience across sleep, mental health, and daily functioning EXTON, PA,
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European
High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie’s Rinvoq continue to generate strong future
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON,
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval
